ホーム>>Signaling Pathways>> PI3K/Akt/mTOR Signaling>> PI3K>>Parsaclisib (INCB050465)

Parsaclisib (INCB050465) (Synonyms: INCB050465)

カタログ番号GC32916

パルサクリシブ (INCB050465) (INCB050465) は、PI3Kδ の強力で選択的な経口活性阻害剤であり、1 mM ATP で 1 nM の IC50 を有します。パルサクリシブ (INCB050465) は、他の PI3K クラス I アイソフォームよりも約 20000 倍の選択性を示します。パルサクリシブ (INCB050465) は、再発または難治性の B 細胞性悪性腫瘍の研究に使用できます。

Products are for research use only. Not for human use. We do not sell to patients.

Parsaclisib (INCB050465) 化学構造

Cas No.: 1426698-88-5

サイズ 価格 在庫数 個数
1mg
$106.00
在庫あり
5mg
$234.00
在庫あり
10mg
$378.00
在庫あり
25mg
$720.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Parsaclisib is a potent and selective PI3Kδ inhibitor, with an IC50 of 1 nM at 1 mM ATP, and shows appr 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ and 57 other kinases.

Parsaclisib (INCB050465) is a potent and selective PI3Kδ with an IC50 of 1 nM at 1 mM ATP, and shows appr 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ and 57 other kinases. Parsaclisib displays significant activity with IC50 values ranging from 0.2 to 2 nM in B and T cell proliferation aaasys. Parsaclisib inhibits proliferation of several DLBCL and MCL cell lines in vitro (EC50 < 10 nM)[1].

[1]. Niu Shin, et al. Abstract 2671: INCB050465, a novel PI3Kδ inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL. Cancer Research. 2015, Aug. 75(15).

レビュー

Review for Parsaclisib (INCB050465)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Parsaclisib (INCB050465)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.